US 12,459,920 B2
Targeted protein degradation
Elisa Liardo, Basel (CH); Laura Ann McAllister, Basel (CH); and Bernhard Fasching, Basel (CH)
Assigned to Monte Rosa Therapeutics AG, Basel (CH)
Filed by Monte Rosa Therapeutics AG, Basel (CH)
Filed on Apr. 18, 2025, as Appl. No. 19/183,531.
Application 19/183,531 is a continuation of application No. PCT/US2024/039292, filed on Jul. 24, 2024.
Claims priority of provisional application 63/528,823, filed on Jul. 25, 2023.
Prior Publication US 2025/0243180 A1, Jul. 31, 2025
Int. Cl. C07D 401/12 (2006.01); A61K 31/506 (2006.01); A61P 29/00 (2006.01)
CPC C07D 401/12 (2013.01) [A61K 31/506 (2013.01); A61P 29/00 (2018.01); C07B 2200/09 (2013.01)] 5 Claims
 
1. A compound having the structure:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.